Blennow K - Search Results

1

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, Müller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Benkert P, et al. Among authors: blennow k. Lancet Neurol. 2022 Mar;21(3):246-257. doi: 10.1016/S1474-4422(22)00009-6. Lancet Neurol. 2022. PMID: 35182510

2

A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia.

Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, Gottfries CG, Blennow K. Skoog I, et al. Among authors: blennow k. Neurology. 1998 Apr;50(4):966-71. doi: 10.1212/wnl.50.4.966. Neurology. 1998. PMID: 9566380

3

Neurofilament protein levels in CSF are increased in dementia.

Rosengren LE, Karlsson JE, Sjögren M, Blennow K, Wallin A. Rosengren LE, et al. Among authors: blennow k. Neurology. 1999 Mar 23;52(5):1090-3. doi: 10.1212/wnl.52.5.1090. Neurology. 1999. PMID: 10102440

4

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H. Blennow K, et al. Lancet Neurol. 2003 Oct;2(10):605-13. doi: 10.1016/s1474-4422(03)00530-1. Lancet Neurol. 2003. PMID: 14505582 Review.

5

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Zetterberg H, Wahlund LO, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2003 Nov 27;352(1):67-9. doi: 10.1016/j.neulet.2003.08.011. Neurosci Lett. 2003. PMID: 14615052

6

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. Prince JA, et al. Among authors: blennow k. Neurology. 2004 Jun 8;62(11):2116-8. doi: 10.1212/01.wnl.0000128088.08695.05. Neurology. 2004. PMID: 15184629

7

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.

Zetterberg H, Andreasen N, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2004 Sep 2;367(2):194-6. doi: 10.1016/j.neulet.2004.06.001. Neurosci Lett. 2004. PMID: 15331151

8

Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results.

Zetterberg H, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurol Sci. 2004 Dec;25(5):301-2. doi: 10.1007/s10072-004-0358-5. Neurol Sci. 2004. PMID: 15624089 No abstract available.

9

Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease.

Blennow K, Johansson A, Zetterberg H. Blennow K, et al. Int J Mol Med. 2005 Dec;16(6):1147-9. Int J Mol Med. 2005. PMID: 16273298

10

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Hansson O, et al. Among authors: blennow k. Lancet Neurol. 2006 Mar;5(3):228-34. doi: 10.1016/S1474-4422(06)70355-6. Lancet Neurol. 2006. PMID: 16488378

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,194 results

Search Page

Filters